Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole Dosing Regimens for Nocturnal Heartburn in GERD
NCT00553449Phase 3Completed
- Sponsor
- Janssen Ortho
- Start
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Janssen Ortho. Primary endpoint: Mean Nocturnal Heartburn Score at 4 weeks. Started Jul 2004; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00553449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553449.